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Methods: Pre- and postprocedural MSCT was performed in 40 patients. TAVI size
selection was done on the basis of anulus cross sectional measurements by MSCT so that
the nominal TAVI device CSA always exceeded the anNulus CSA. In preprocedural data
sets we determined the valve calcium score, the CSA and the ovality index of the aortic
anulus. In postprocedural data sets maximum and minimum diameter and the degree of
circularity at three levels (ventricular end, anulus, aortic end) was determined.
Results: The average expansion ratio of the Edwards Sapien XT device was 95% and the
circularity Index was 97%. In multivariate regression analysis neither calcium score nor
ovality index of the native anulus were associated with under or non circular expansion
of the device. The only parameter predicting underexpansion was the degree of
oversizing. Underexpansion of the device was not associated with increased transaortic
pressure gradients or with the incidence of paravalvular aortic regurgitation. The degree
of oversizing was however positiveley associated with the incidence of new conduction
disturbances. In the entire cohort no aortic regurgitation  mild was observed.
Conclusions: MSCT guided TAVI device sizing is associated with almost complete and
symmetric expansion of the Edwards Sapien XT device and the absence of significant
aortic regurgitation. Calcification or ovality of the native anulus do not influence the
expansion pattern. To rigorous device oversizing however is associated with new
conduction disturbances and device underexpansion.
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Impact of New Conduction Defect After TAVI on Left Ventricular Function
at 1-Year Follow-up
Rainer Hoffmann1, Rüdiger Autschbach1, Ralf Herpertz1, Sharam Lotfi1,
Nikolaus Marx1
1University Aachen, Aachen, Germany
Background: New left bundle branch block (LBBB) or need for permanent pacing due
to AV-block are frequent after transcatheter aortic valve implantation (TAVI). This study
evaluated the impact of new conduction defect after TAVI on the evolution of left
ventricular (LV) function during one year follow-up.
Methods: A total of 90 consecutive patients treated with TAVI and 12 months
echocardiographic follow-up were included in the study. In 39 patients a new conduction
defect (new LBBB or need for permanent pacemaker activity) persisted one month after
TAVI. In 51 patients no persistent new conduction defect was observed. 2D echocardi-
ography using parasternal short-axis, apical 4-chamber and 2-chamber views was
performed before TAVI and at 1 year follow-up to determine left ventricular volumes and
ejection fraction based on Simpson’s rule. Speckle-tracking echocardiography was
applied using standard LV short-axis images to assess the effect of new conduction defect
on time-to-peak radial strain of different LV segments as parameter of LV dyssynchrony.
Results: New conduction defect resulted in marked heterogeneity in time-to-peak strain
between the 6 analysed short-axis segments. During one year follow-up after TAVI there
was a significant increase in LVEF in patients without new LBBB (5311% pre to
5910% at follow-up; p0.001), while there was no change in LVEF in patients with
new conduction defect (5211% pre to 5112% at follow-up, p0.740). Change in LV
endsystolic volume was also significantly different between patient groups (1.014.2
vs. 11.215.7 ml, p0.042). New conduction defect was an independent predictor of
reduced LVEF at 12 months follow-up after TAVI.
Conclusions: LVEF improves after TAVI for treatment of severe aortic stenosis in
patients without new conduction defect. In patients with a new conduction defect after
TAVI, there is no improvement in LVEF at follow-up.
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Assessment of Doubtful Aortic Stenosis by Measuring Simultaneous
Transaortic Pressure: A Pilot Study With Fractional Flow Reserve Guidewire
Romain Chopard1, Marie-France Seronde1, Sebastien Janin1,
Philoktimon Plastaras1, Nicolas Meneveau1, Francois Schiele1
1University Hospital Besancon, France, Besancon, France
Background: Transthoracic echocardiography (TTE) is the reference technique for
evaluating aortic stenosis (AS), but in certain cases, estimation of the average gradient and
aortic valve area can be difficult. We aimed to assess the feasibility and utility of
measuring simultaneous transaortic pressure using a fractional flow reserve (FFR)
guidewire in doubtful aortic stenosis.
Methods: Between January 2009 and December 2011, 57 patients with symptoms
possibly related to severe AS that was poorly evaluated by echocardiography underwent
right and left heart catheterization for assessment of aortic valve area with the Gorlin &
Gorlin formula. Transaortic pressure was obtained by 2 invasive methods, namely
conventional pullback method from the left ventricle (LV) towards the aorta (PM) with
subsequent computerized superposition of the pressure curves, and (2) simultaneous
method using a FFR wire introduced into the LV (SM).
Results: Reasons for inaccurate assessment by echocardiography were atrial fibrillation
(75%) and/or low LV ejection fraction (38%). Results of evaluation of mean aortic valve
gradient and aortic valve area are summarized in the table below. Agreement between
methods (using the kappa coefficient) for severe aortic stenosis defined by an aortic-valve
area 0.6 cm2/m2 was 0.36 between SM and PM, 0.07 between SM and TTE, and0.12
between PM and TTE. These findings led to a decision to change therapeutic strategy in
8 patients (14%).
Conclusions: Simultaneous measurement of trans-aortic pressure using a FFR guidewire
is feasible and may be an attractive and accurate method for evaluation of doubtful aortic
stenosis.
Simultaneous
pressure
Pullback
method
Echocardiographic
measurements
Mean aortic valve
gradient, mmHg
30.514.4 23.69.9 28.88.0
p vs Pullback 0.0001 — 0.0002
p vs echo 0.241 — —
Aortic valve area,
cm2/m2
0.460.2 0.480.15 0.490.1
p vs Pullback 0.003 — 0.529
p vs echo 0.074 — —
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Hospitalisations costs of TAVI in Belgium. An analysis in one University
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Diana De Graeve1, Raf Van Gestel2, Carmen Ryvers1, Inez Rodrigus3,
Johan Bosmans4
1University Of Antwerp, Antwerpen, Belgium, 2University of Antwerp, Turnhout,
Antwerp, 3Antwerp University Hospital, Edegem, Belgium, 4University Hospital
Antwerp, Antwert, Belgium
Background: Patients with severe aortic stenosis, but who are not good candidates for
surgical aortic valve replacement can be treated with trans-catheter aortic valve implan-
tation (TAVI). This latest technology however comes at a considerable cost. The objective
of the current study is to calculate and analyse these costs.
Methods: Data were retrospectively collected from all patients who underwent a
transaortic valve insertion in the University Hospital Antwerp from December 2007 until
June 2011. Costs of hospitalisation were retrieved on the basis of invoices and patients
characteristics from medical records. Costs were actualized to 2011 using 2011 tariffs and
determinants analysed (Wilcoxon rank sum test and Spearman rho’s correlation).
Results: 89 patients were included. Analyses are performed on 86 patients with complete
cost data. All interventions were done by a single physician using Core Valve ®. Mean
age of the patients was 82 years; 73% of patients are in NYHA 3 and 4. Mean costs
amount to €38,521 (sd €8,587) with median costs only slightly smaller (€37,079). The
costs of the valve (€17,090 per valve) and daily nursing and hotel costs (€ 594 per day)
are most important, amounting to respectively 46% and 26% of total costs. There is weak
evidence of a learning effect: costs decrease somewhat over the years (p0.091).
Pulmonary hypertension (p0.04) and hyperlipidemia (0.0049) have a siginificant
association with costs as well. The distribution of costs is not significantly different for
other background characteristics of the patient. (see table 1)
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Discrete variables n (%)
Wilcoxon rank
sum p-value
mean rank of
total costs
Gender (male) 32 (37.2%) .526
NYHA III, IV 62 (72.1%) .472
Atrial fibrillation 19 (22.1%) .735
Carotid disease 4 (4.7%) .335
CAD 42 (48.8%) .140
Porcelain aoreta 5 (5.8%) .789
PVD 9 (10.5%) .239
Diabetes 21 (24.4%) .591
Pulmonary hypertension 14 (16.3%) .037 56.21 with
pht.
41.03 without
pht.
Mediastinal radiation 6 (7.0%) .919
Hyperlipidemia 29 (33.7%) .004 32.59 with hl.
49.05 without
hl.
COPD 14 (16.3%) .194
Renal failure 11 (12.8%) .781
Angina 18 (20.9%) .531
Previous MI 10 (11.6%) .215
Previous stroke-TIA 2 (2.3%) .626
Previous pacemaker 2 (2.3%) .071 12 with pm.
44.25 without
pm.
Previous CABG 25 (29.1%) .898
Previous valve surgery 4 (4.7%) .743
Previous PCI 17 (19.8%) .371
Year of intervention .091
2007-2009 43 (50.0%) 47.77
2010 20 (26.7%) 44.12
2011 23 (23.3%) 32.44
Continuous variables Mean (sd) Spearman rho’s
p-value
age (years) 81.8 (6.6) .989
log euroscore 25.6 (15.2) .559
AVA (cm2) 0.6 (0.15) .556
Mean grad (mmHg) 25.2 (17.0) .824
LVEF (%) 59.4 (12.7) .899
Conclusions: Total hospitalisation costs of TAVI amount to about €40,000. Main cost
driver is length of stay and valve cost. Costs decrease marginally over time. Most patient
characteristics are not significantly related to total hospitalisation costs.
TCT-812
30-day Outcome of the 18 F-Direct Flow Medical Valve in Patients with
Severe Aortic Stenosis - Results from the DISCOVER Trial
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Klaudija Bijuklic5, Thilo Tuebler6, Thierry Lefevre7
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Milan, Italy, 5Medical Care Center Prof Mathey, Prof Schofer, Hamburg,
Germany, 6Medical Care Center Prof. Mathey, Prof. Schofer, Hamburg, Germany,
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Background: For currently available percutaneous aortic valve prosthesis, device design
limitations and potential misplacement can lead to significant aortic regurgitation, which
can result in severe complications and have an impact on long-term survival. The Direct
Flow Medical (DFM) valve is repositionable and retrievable and has non metallic
inflatable cuff with a conformable design that results in better valve sealing. Compared to
the first generation, the new 18F prosthesis, has a smaller profile, increased radial force
and better handling. We report the first series of high risk patients who received the 18F
DFM transfemoral prosthesis for severe aortic stenosis. Aim of the study was to test the
safety and performance of the 18F Direct Flow Medical valve in high risk patients with
severe aortic stenosis.
Methods: In this prospective, multicenter, non-randomized clinical trial 100 symptomatic
patients with severe aortic stenosis and a logistic Euro-SCORE  20% will be enrolled.
The primary endpoint is freedom from all-cause mortality @ 30 days, secondary
endpoints were device success and safety according to the VARC criteria. Data are
monitored and events adjudicated by independent committees (DMC, CEC). All echo-
cardiograms and angiograms were assessed by an independent Core Laboratory.
Results: The study started in January 2012 in 5 centers in Europe. Five additional centers
will follow. As of May 2012, 25 patients have been enrolled (mean age 84.9 y, 76-95 yrs,
mean logistic Euro-Score 27.9%, mean STS 11%). The primary endpoint of freedom from
death at 30 days was achieved in all 25 patients. The valve was retrieved and reimplanted
in 4 patients. At present, 10 pts had core lab evaluation, revealing a mean transvalvular
gradient at 30 days of 11 mmHg. There was no aortic regurgitation in 8 pts and 2 had trace
aortic regurgitation.
Conclusions: The 18F DFM valve can be safely implanted, repositioned and, if
necessary retrieved in high risk patients with severe aortic stenosis. Preliminary results
suggest excellent hemodynamic performance with abolishing significant aortic regurgi-
tation. The results of the completed study will be available at TCT 2012.
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Long-term performance of a transfemorally implantable nonmetallic,
retrievable and repositionable aortic valve in patients with severe aortic
stenosis 4 Year Follow-Up of the 22 F-Direct Flow Medical Valve
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Prof. Schofer, Hamburg, Germany, 3Hamburg University, Hamburg, Germany,
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Background: The Direct Flow Medical (DFM) valve is repositionable and retrievable.
The non metallic inflatable and conformable design of the valve results in better sealing
but in less radial force which may have an impact on stability and valve function over
time. Aim of the study was to evaluate the 4-year clinical and echocardiographic outcome
of the first generation 22F-DFM percutaneous aortic valve.
Methods: From 2007 to 2008 31 symptomatic high-risk for surgery patients (mean age
824y) with severe aortic stenosis and a mean logistic EuroSCORE of 297% were the
subject of this analysis. Clinical, echocardiographic and hemodynamic follow-up were
obtained during 4 years.
Results: Survival rates were 81%, 69%, 60%, and 54% at 1,2,3,4 years, respectively. At
4 years, 83% of the patients, who survived, were in NYHA-class I, 17% in class II.
Echocardiography revealed a significant decrease of the mean gradient from baseline
(49.113.8 mmHg) to 30 days (19.16.8 mmHg, p  0.001), which remained stable
over 4 years. At 4-year follow-up, 80% of the patients had no aortic regurgitation, 20 %
had trace aortic regurgitation.
Conclusions: In this preliminary series, the first generation of the nonmetallic, reposi-
tionable and retrievable 22F-DFM valve was associated with acceptable clinical outcome
and stable hemodynamic performance with no aortic regurgitation in the majority of
patients.
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Health Related Quality of Life Following Transcatheter Aortic Valve
Implantation: Results from the CoreValve ADVANCE Study
Johan Bosmans1, Ulrich Gerckens2, Peter Wenaweser3, Corrado Tamburino4,
Stephen Brecker5, Robert Bauernschmitt6, Axel Linke7
1University Hospital Antwerp, Antwert, Belgium, 2Bonn Community Hospital,
Bonn, Germany, 3University Hospital Bern, Bern, Switzerland, 4University of
Catania, Catania, Italy, 5St. George’s Hospital, London, United Kingdom, 6ISAR
Heart Center, Munich, Germany, 7University Hospital Leipzig, Leipzig, Germany
Background: Percutaneous transcatheter aortic valve implantation (TAVI) is associated
with favorable safety and efficacy outcomes in older patients at high risk for surgical AV
replacement. Health Related Quality of life (HRQoL) can be at least, if not more,
important than quantity of life in an elderly patient population, often frail, and with
multiple comorbidities. The Medtronic CoreValve ADVANCE is a prospective, multi-
center, 100% monitored study evaluating “real world” patients with severe aortic stenosis
treated with the CoreValve System (Medtronic, Minneapolis, MN). The HRQoL
measures collected in the ADVANCE study represents the largest, rigorously reported
cohort of HRQoL findings in the TAVI literature.
Methods: From March 2010 to July 2011, the ADVANCE study enrolled 1015 patients
at 44 experienced centers in Western Europe, Asia, and South America. HRQoL was
evaluated using the SF-12 and the EQ-5D, 2 general validated questionnaires. Results of
the measurements at baseline, 1 and 6 months are reported.
Results: Baseline clinical characteristics were: 50.6% female, age 81.16.4 y, log
EuroSCORE 19.212.4, 79.6% NYHA Class III/IV, 22.6% COPD, 21.4% prior CABG,
14.6% renal failure, and 12.9% cerebrovascular disease. Compared with baseline,
physical and mental summary score (PCS and MCS) measures and the EQ-5D index
significantly improved at 1 and 6 months.
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